Grace Therapeutics Inc (GRCE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.78-1.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GRCE
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(14.1) + peer(0.2*0.9) + term(0.0) → 5.12% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 7 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On August 13, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On June 18, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for p…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On February 12, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “file…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On November 13, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “fil…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 12, 2025, Grace Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Sec…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On June 23, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 13, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On November 13, 2024, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall no…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 9, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On June 21, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal year ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 12, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of S…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On November 13, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 11, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On June 23, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal year ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 14, 2023, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Sect…
Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.” On November 14, 2022, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of…